-+ 0.00%
-+ 0.00%
-+ 0.00%

TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq review

PUBT·07/02/2026 20:07:07
Listen to the news
TransCode Therapeutics adjourns annual shareholder meeting to July 20 pending Nasdaq review
  • TransCode Therapeutics adjourned its 2026 annual shareholder meeting to July 20 from July 2.
  • Delay tied to Nasdaq Listing Rule 5110(a) review required before a vote on converting Series A and Series B non-voting preferred stock.
  • Preliminary vote tallies showed all meeting proposals had enough shareholder support for passage.
  • Nasdaq has not completed its review of the company’s initial listing application, creating timing uncertainty.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Transcode Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-26-080311), on July 02, 2026, and is solely responsible for the information contained therein.